Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Heres

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 15, 2012
Patients' acceptance of the deltoid application of risperidone long-acting injectionStephan Heres, Teresa Frobose, Johannes Hamann, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|March 14, 2023
Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient settingKatharina Müller, Florian Schuster, Silvia Krumm, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2013
Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine useStephan Heres, Liana Don, Miroslav Herceg, et al.
Schizophrenia Bulletin|April 5, 2015
Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose MethodStefan Leucht, Myrto Samara, Stephan Heres, et al.
Schizophrenia Bulletin Open|June 1, 2026
Impact of Healthcare Professional Role and Care Setting on Attitudes Toward Long-Acting Injectable Antipsychotics for Schizophrenia: A Subgroup Analysis of the Multinational ADVANCE StudyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.
European Archives of Psychiatry and Clinical Neuroscience|February 17, 2020
Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trialMaximilian Huhn, Claudia Leucht, Philipp Rothe, et al.
BMC Psychiatry|March 15, 2020
Attitudes of European physicians towards the use of long-acting injectable antipsychoticsMaxine X Patel, Nawal Bent-Ennakhil, Christophe Sapin, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 1, 2015
The SWITCH study: rationale and design of the trialStephan Heres, Diana Meliu Cirjaliu, Liana Dehelean, et al.
Schizophrenia Bulletin|May 13, 2022
Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysisAnna Ceraso, Jessie Jingxia Lin, Johannes Schneider-Thoma, et al.
Patient Preference and Adherence|January 31, 2018
Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scalingJohn Fp Bridges, Kathleen Beusterien, Stephan Heres, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 15, 2012
Patients' acceptance of the deltoid application of risperidone long-acting injectionStephan Heres, Teresa Frobose, Johannes Hamann, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|March 14, 2023
Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient settingKatharina Müller, Florian Schuster, Silvia Krumm, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2013
Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine useStephan Heres, Liana Don, Miroslav Herceg, et al.
Schizophrenia Bulletin|April 5, 2015
Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose MethodStefan Leucht, Myrto Samara, Stephan Heres, et al.
Schizophrenia Bulletin Open|June 1, 2026
Impact of Healthcare Professional Role and Care Setting on Attitudes Toward Long-Acting Injectable Antipsychotics for Schizophrenia: A Subgroup Analysis of the Multinational ADVANCE StudyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.
European Archives of Psychiatry and Clinical Neuroscience|February 17, 2020
Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trialMaximilian Huhn, Claudia Leucht, Philipp Rothe, et al.
BMC Psychiatry|March 15, 2020
Attitudes of European physicians towards the use of long-acting injectable antipsychoticsMaxine X Patel, Nawal Bent-Ennakhil, Christophe Sapin, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 1, 2015
The SWITCH study: rationale and design of the trialStephan Heres, Diana Meliu Cirjaliu, Liana Dehelean, et al.
Schizophrenia Bulletin|May 13, 2022
Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysisAnna Ceraso, Jessie Jingxia Lin, Johannes Schneider-Thoma, et al.
Patient Preference and Adherence|January 31, 2018
Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scalingJohn Fp Bridges, Kathleen Beusterien, Stephan Heres, et al.
Pageof 9